MBBS FRACP FRCPA

• Consultant Haematologist

Associate Professor Ashish Bajel is a Consultant Haematologist and Bone Marrow Transplant Physician at The Royal Melbourne Hospital. He graduated from University of Mumbai, India followed by specialist training in internal medicine and haematology culminating in a DM (Clinical Haematology). He subsequently became a fellow of The Royal College of Pathologists (RCPA) and Physicians (RACP) specializing in clinical and laboratory Haematology.

Assoc. Prof Bajel is actively involved in clinical research as a principal investigator and associate investigator in a wide range of clinical trials at the Royal Melbourne Hospital.

---

"Assoc. Prof Bajel has expertise across a range of benign and malignant haematological conditions with a special emphasis on lymphomas, myelomas, myelodysplastic and myeloproliferative disorders. He also consults on patients with clotting and bleeding disorders"

---

Select Publications

1. Ananda-Rajah MR, Grigg A, Downey MT, Bajel A, et al. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia / myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica. 2012 Mar; 97(3):459-63.
2. Bajel A, Yin Lin M, Hill PA, Goodman D et al. IgA nephropathy associated with cutaneous T cell lymphoma. Leuk Lymphoma. 2009 Dec; 50(12):2083-5.
3. Edison ES, Bajel A, Chandy M. Iron homeostasis: new players, newer insights. Eur J Haematol. 2008 Dec; 81(6):411-24. Review
4. Bajel A, George B, Mathews V, Viswabandya A, et al. Treatment of Children with Acute Lymphoblastic Leukemia in India using a BFM Protocol. Pediatr Blood Cancer. 2008 Nov; 51(5):621-5.
5. Bajel A, George B, Mathews V, Viswabandya et al. Adult ALL: treatment outcome and prognostic factors in an Indian population using a modified German ALL (GMALL) protocol. Leukemia. 2007 Oct; 21(10):2230-5
6. Mathews V, George B, Lakshmi KM, Viswabandya A, et al. Single-agent arsenic trioxide in the treatment of newly diagnosed acute promyelocytic leukemia: durable remissions with minimal toxicity. Blood. 2006 Apr 1; 107(7):2627-32.

---

Memberships

• American Society of Haematology (ASH)
• Australasian Leukemia and Lymphoma Group (ALLG)
• Haematology Society of Australasia and New Zealand (HSANZ)

MBBS PhD FRACP FRCPA

• Clinical and Laboratory Haematologist

Isaac Goncalves graduated from the University of Melbourne and completed specialist clinical and laboratory haematology training at the Alfred Hospital. He was the recipient of the Monash University postgraduate excellence award to complete his PhD in the field of platelets and thrombosis. This work resulted in a number of peer-reviewed publications in high-standing medical journals, including Nature Medicine.

---

Isaac is a consultant haematologist at Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, his area of interest includes both malignant and benign haematology, with a specific focus on clotting and bleeding disorders. Isaac remains actively involved in research, as a principal investigator in research studies and clinical trials at Peter MacCallum Cancer centre and The Royal Melbourne Hospital.

Currently Isaac sees and treats patients at the Royal Melbourne Hospital private consulting rooms.

---

Isaac inspires to provide a professional and genuine patient-centred service.

---

MBBS PhD FRACP FRCPA

• Clinical and Laboratory Haematologist

After graduating from Medicine at the University of Melbourne, Kylie undertook specialist haematology training in Melbourne and is a fellow of both the Royal Australian College of Physicians (FRACP) and the Royal College of Pathologists of Australia (FRCPA).

---

Kylie was inspired to complete a Ph.D. at the Walter and Eliza Hall Institute of Medical Research /University of Melbourne 2007 focusing on new drugs for leukaemia and lymphoma and the biology of platelets. Kylie continues her research as the Victorian Cancer Agency Fellow at WEHI.

Her work has been published in prestigious international journals and recognized by awards including the Premiers Award for Medical Research in 2009 and the L’Oreal for Women in Science Award in 2012.

Kylie has an appointment as a Clinical Haematologist at the Royal Melbourne Hospital and currently looks after patients with all aspects of both malignant and benign haematological disorders. In particular her main interests are Leukaemia (including CLL / CML and acute leukaemias), Lymphoma, Myeloma, Haemoglobinopathies and disorders of Iron metabolism and blood clotting / platelets.

Kylie has an active interest in clinical trials and in particular translational research relating to her dual role at WEHI / RMH. These include both phase II and phase III clinical trials in leukaemia and lymphoma. Kylie is also actively involved in clinical trial development through the ALLG.

Currently Kylie sees and treats patients at the Royal Melbourne Hospital private consulting rooms.

---

Kylie has an interest in all aspects of haematology, including Leukaemia (including CLL / CML and acute leukaemias), Lymphoma, Myeloma, Haemoglobinopathies and disorders of Iron metabolism and blood clotting / platelets.

---

Qualifications

• 2012 NIH Clinical Research Training Course
• 2009 Specialist Certificate in Clinical Research (Oncology)
  First Class Honours, The University of Melbourne
• 2007 Doctor of Philosophy (Medical Biology)
  Thesis entitled 'Investigations into the regulation and modulation of apoptosis in haematological malignancy'
  The University of Melbourne / Walter & Eliza Hall Institute of Medical Research
• 2004 Fellow - Royal Australasian College of Physicians
• 2004 Fellow - Royal College of Pathologists of Australasia
• 1996 Bachelor of Medicine and Bachelor of Surgery

---

Awards

• 2012 L'Oreal Australia For Women In Science Fellowship - Winner
• 2011 L'Oreal Australia For Women In Science Fellowship - Highly commended
• 2009 Named in 'Melbourne's Top 100 Most Influential People' – The Age
• 2009 Premier's Award for Health and Medical Research, Victorian State Government
• 2008 Young Tall Poppy Science Award, Victorian State Government
• 2007 Student Seminar prize, Walter & Eliza Hall Institute of Medical Research
• 2006 Cleveland Young Investigator's Award, Royal Melbourne Hospital
• 2006 Albert Baikie Memorial Medal – Haematology Society Australia & New Zealand

---

Professional Memberships

• Victoria Cooperative Oncology Group: Haemato-oncology committee (2012 - present)
• Victorian Comprehensive Cancer Centre Emergency Admissions Committee (2011-present)
• Australian Leukaemia Lymphoma Group (2010-present)
• International Society of Experimental Hematology (2007 – present)
• Melbourne Health Human Ethics Expert Scientific Review Panel (2010 – present)
• Victorian Cancer Agency Early Careers Innovators Network (2007 – 2008)
• American Society of Hematology (2004 – present)
• Haematology Society of Australia and New Zealand (2001 – present)

---

Selected Publications - Top 10 (All original studies)

1. James E. Vince, W. Wei-Lynn Wong, Ian Gentle, Ramanjaneyulu Allam, Lorraine O’Reilly, Kylie D Mason, Olaf Gross, Greta Guarda, Rosa Castillo, Georg Hacker, John Silke and Jurg Tschopp. Inhibitor of apoptosis (IAP) proteins regulate IL-1 activation. Immunity 2012, 36 (2), 215-227 (impact factor 24.22)
2. Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, Fairlie D, Grigg AP, Seymour JF, Szer J, Huang DCS, Roberts AW; The BH3 mimetic compound ABT-737 Synergizes with a Range of Cytotoxic Chemotherapy Agents in Chronic Lymphocytic Leukemia. Leukemia, 2009; 23(11): 2034-41
3. Kylie D. Mason, Cassandra J. Vandenberg, Clare L. Scott, Andrew H. Wei, Suzanne Cory, David C.S. Huang, Andrew Roberts; In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. PNAS 2008; 105(46): 17961-6.
4. Mason KD, Juneja SK; Go with the flow for monitoring response in myeloma patients with minimal residual disease. Leukemia and Lymphoma, Feb 2008; 49(2): 117-8.
5. Mason KD, Juneja SK; The value and limitations of immunophenotyping in Acute Myeloid Leukaemia. Educational supplement RCPA Quality Assurance Program. May 2007
6. Mason KD, Carpinelli M, Fletcher J, Collinge J, Hilton A, Ellis S, Kelly P, Ekert P, Metcalf D, Roberts AW, Huang DCS, Kile BT ; Programmed anuclear cell death delimits platelet life span. Cell, 2007; 128, 1173-1186. Cited as ‘Exceptional’ by Faculties of 1000 in Medicine and Biology.
7. van Delft M, Wei A, Mason KD, Vandenberg CJ, Chen L, Czabotar PE, Willis S, Scott CL, Day C, Cory S, Adams J, Roberts AW, Huang DCS; The BH3 mimetic ABT-737 targets selective Bcl‑2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell, 2006; 10 (5) 389-399. Cited as ‘Must Read’ by Faculties of 1000 in Biology.
8. Mason KD, Juneja SJ, Szer J; The immunophenotype of Acute Myeloid Leukaemia: Is there a relationship to prognosis? Blood Reviews, 2006 (20) 71-82.
9. Mason KD, Szer J; Investigating patients with Macrocytosis. Medicine Today, 2005 6(12) 35-39.
10. Mason KD, Juneja S; Spontaneous rupture of the spleen in the blastic variant of mantle cell lymphoma. Journal of Clinical and Laboratory Haematology, 2003, 25(4), 263-265.